Review Article

Efficacy of Intermittent or Continuous Very Low-Energy Diets in Overweight and Obese Individuals with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analyses

Yi Shan Huang,1 Qiyan Zheng,1 Huisheng Yang,2 Xinwen Fu,1 Xueqin Zhang,1 Chenhui Xia,1 Zebing Zhu,1 Yu Ning Liu,1,3 and Wei Jing Liu1,4

1Renal Research Institution of Beijing University of Chinese Medicine, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing 100700, China
2Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing 100700, China
3Department of Endocrinology Nephropathy, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing 100700, China
4Institute of Nephrology, Zhanjiang Key Laboratory of Prevention and Management of Chronic Kidney Disease, Guangdong Medical University, Zhanjiang, Guangdong 524001, China

Correspondence should be addressed to Yu Ning Liu; yunin1946@sina.com and Wei Jing Liu; liuweijiang-1977@hotmail.com

Received 8 September 2019; Accepted 7 January 2020; Published 29 January 2020

Guest Editor: Ruozhi Zhao

Copyright © 2020 Yi Shan Huang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. This study is aimed at investigating the efficacy of a very low-energy diet (VLED) in overweight and obese individuals with type 2 diabetes mellitus (T2DM). Methods. We thoroughly searched eight electronic resource databases of controlled studies concerning the efficacy and acceptability of intermittent or continuous VLEDs in patients with T2DM compared with other energy restriction interventions. Results. Eighteen studies (11 randomized and seven nonrandomized controlled trials) with 911 participants were included. The meta-analyses showed that compared with a low-energy diet (LED) and mild energy restriction (MER), VLED is superior in the reduction of body weight (mean difference (MD) \(\Delta MD = \Delta -2.77\), 95% confidence interval (CI) \(95\% CI_{\Delta MD} = -4.81\) to \(-0.72\), \(P_{\Delta MD} = 0.008\), \(MD_{\Delta MER} = 0.55\), 95%CI\(_{\Delta MER} = -10.05\) to \(-3.39\), \(P_{\Delta MER} < 0.0001\)), blood glucose (MD\(_{\Delta LED} = -1.18\), 95%CI\(_{\Delta LED} = -2.05\) to \(-0.30\), \(P_{\Delta LED} = 0.008\), \(MD_{\Delta MER} = -6.72\), 95%CI\(_{\Delta MER} = -10.05\) to \(-3.39\), \(P_{\Delta MER} < 0.0001\)), and triglyceride (TG) (MD\(_{\Delta LED} = -0.35\), 95%CI\(_{\Delta LED} = -0.58\) to \(-0.12\), \(P_{\Delta LED} = 0.002\), \(MD_{\Delta MER} = -5.55\), 95%CI\(_{\Delta MER} = -9.39\) to \(-0.17\), \(P_{\Delta MER} = 0.005\)) levels at the end of the intervention. After the follow-up (1–5 years), no obvious difference in weight loss (MD\(_{\Delta LED} = -0.84\), 95%CI = \(-3.01\) to \(1.32\), \(P = 0.45\), \(I^2 = 0\%\)) and TG level (MD\(_{\Delta LED} = 0.55\), 95%CI\(_{\Delta LED} = -0.55\) to \(0.06\), \(P = 0.12\), \(I^2 = 0\%\)) between VLEDs and LEDs was evident, but VLED is more effective in glycemic control (MD\(_{\Delta LED} = -1.43\), 95%CI\(_{\Delta LED} = 9.65\) to \(-0.20\), \(P = 0.02\)). Compared to bariatric surgery, VLEDs offered comparable effects on weight loss (MD\(_{\Delta LED} = 2.51\), 95%CI\(_{\Delta LED} = 9.52\) to \(14.54\), \(P = 0.37\)), glycemic control (MD\(_{\Delta LED} = -0.22\), 95%CI\(_{\Delta LED} = 0.06\), \(P = 0.22\)), and insulin resistance improvement (MD\(_{\Delta LED} = 0\), 95%CI\(_{\Delta LED} = -0.74\) to \(0.17\), \(P = 0.7\)). Conclusion. Dietary intervention through VLEDs is an effective therapy for rapid weight loss, glycemic control, and improved lipid metabolism in overweight and obese individuals with T2DM. Thus, VLEDs should be encouraged in overweight and obese individuals with T2DM who urgently need weight loss and are unsuitable or unwilling to undergo surgery. As all outcome indicators have low or extremely low quality after GRADE evaluation, further clinical trials that focus on the remission effect of VLEDs on T2DM are needed.
1. Introduction

It is well known that obesity is a major risk factor for type 2 diabetes mellitus (T2DM) [1] and the majority of patients with T2DM are overweight or obese [2]. Obesity management is confirmed as an effective strategy in the prevention and remission of T2DM [3].

Multiple strategies including diet, physical activity, behavioural therapy, pharmacologic therapy, and bariatric surgery are recommended for obesity management [3]. In previous evidence-based clinical guidelines, dietary modification is recommended as a fundamental aspect of diabetes care, based on its benefits on glycemia and HbA1c levels [4]. Recently, several studies suggest that short-term and more extreme dietary energy restriction aiming on intensive weight loss can even reverse some cases of T2DM [5–7]. Very low-energy diet (VLED) has been confirmed as an effective and safe option for weight loss in obese individuals [8]. There is no standard definition of a VLED programme across different countries and continents [9–11]. However, a VLED is generally defined as a very low total energy intake (≤800 kcal/day) [8, 10]. Recently, a growing body of studies focus on the efficacy and acceptability of VLEDs in patients with T2DM who are overweight or obese [12–14] and propose that VLEDs may be an underutilized therapy for patients with T2DM. Intermittent VLED is an alternative strategy of continuous VLEDs for T2DM, which typically involves periods of VLEDs interchanged by periods of ad libitum energy intake or mild energy restriction (MER, a slight diet intervention method which provides energy less than ad libitum energy intake but more than 1600 kcal/day) [15, 16]. The efficacy of both intermittent and continuous VLED should be considered.

A low-energy diet (LED) containing 800–1600 kcal/day is also considered an option of clinical obesity management of patients with T2DM [17, 18], but the difference in efficacy and safety between VLEDs and LEDs is rarely discussed. Bariatric surgery is recommended for obese patients (body mass index (BMI), 35.0–39.9 kg/m²) with T2DM who did not achieve durable weight loss and improvement in comorbidities with reasonable surgical methods [3]. For example, Roux-en-Y gastric bypass (RYGB), as currently one of the most effective types of bariatric surgery, achieves energy limitation by reducing stomach capacity and reducing dietary intake. However, bariatric surgeries have more adverse effects and complications compared with energy restriction strategy. Moreover, VLEDs may produce a similar effect on glycemic control, β-cell function, and insulin sensitivity as bariatric surgeries. Thus, it is necessary to evaluate the efficacy of VLEDs compared with other methods of energy restriction in overweight and obese individuals with T2DM.

A previous systematic review among overweight and obesity individuals with T2DM found that VLED has benefits of weight loss and glycemic control [19]. However, the systematic review included a small number of participants, and the long-term effect of VLEDs is unclear. Another recently published systematic review found that VLED programmes in children and adolescents with obesity induce short- to medium-term weight loss and also demonstrated significant improvements in diabetic outcomes, such as HbA1c and glucose levels [10]. Recently, several clinical studies have been conducted to compare VLEDs with other energy restriction methods. Thus, it is necessary to investigate the efficacy of VLEDs in overweight and obese adult individuals with T2DM. Our systematic review and meta-analyses are aimed at clarifying the effect of VLEDs on weight loss, glycemic control, and blood lipid levels in overweight and obese individuals with T2DM and further exploring the long-term efficacy of VLEDs to provide more substantial evidence in the clinical application of VLEDs.

2. Materials and Methods

2.1. Search Strategy. We comprehensively searched PubMed, EMBASE, Cochrane Library, Web of Science, SINOMED, China National Knowledge Infrastructure, WanFang, and Chongqing VIP Information databases from inception until July 2019 for clinical trials investigating intermittent or continuous VLEDs for overweight and obese adults with T2DM. Additional studies were searched in the reference lists of all identified publications, including relevant meta-analyses and systematic reviews.

2.2. Inclusion Criteria. Published and unpublished randomized controlled trials (RCTs) and non-RCTs, which are clinical controlled studies evaluating the efficacy of intermittent or continuous VLEDs and qualitative studies exploring the acceptability of, barriers to, and facilitators of VLEDs, were considered for inclusion in this review.

We included clinical studies that satisfied the following criteria: (1) participants in the included studies were overweight or obese (mean BMI ≥ 30 kg/m² or ≥10% above the ideal body weight based on the Metropolitan Life Insurance Company’s tables); (2) adults (aged ≥18 years) had T2DM in older studies using a different measure of obesity; (3) studies used intermittent or continuous VLEDs comprising ≤800 kcal/day in at least one intervention arm; and (4) studies also had to include a control arm receiving other energy control methods, including LEDs (800–1600 kcal/day), bariatric surgery, and MER. We excluded clinical studies with the following features: (1) both the intervention and comparator arms received VLED treatment (except VLEDs after surgical treatment) and (2) the intervention is VLED combined with other weight loss drugs. If a study compared three or more arms, VLED arms were considered to be the intervention and other energy control methods the comparators.

The outcome indicators of this study include the following: (1) weight loss (kg), (2) fasting plasma glucose levels (mmol/l) and change in medication, (3) triglyceride (TG) level (mmol/l), (4) homeostatic model assessment of insulin resistance (HOMA-IR) level, (5) dropout, (6) side effects, and (7) rebound.

2.3. Data Extraction. Two reviewers (YS Huang and XW Fu) independently extracted data from original trial reports using a standardized form. Data extracted included study characteristics (first author, publication year, single center or multicenter, sample size, intervention and control, period of treatment, and follow-up duration), characteristics of
patients (inclusion criteria, background treatments, mean age, proportion of men, baseline weight, and baseline glucose levels), reported outcomes (weight, fasting plasma glucose levels, and adverse events), and information on methodology. We contacted the study authors when we needed to obtain additional information that was unavailable in the online publications or supplementary materials.

2.4. Quality Assessment. Risk of bias of RCTs was assessed using the Cochrane Collaboration’s tool [20]. We evaluated non-RCTs according to the Risk Of Bias In Non-randomised Studies of Interventions (ROBINS-I) tool [21]. Two investigators independently completed the assessments, and discrepancies were discussed with a third party and resolved by consensus.

Additionally, the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework was used to assess the quality of evidence contributing to each network estimate, which characterizes the quality of a body of evidence on the basis of the study limitations, imprecision, inconsistency, indirectness, and publication bias for the primary outcomes [22].

2.5. Statistical Analyses. The data entry and analysis were conducted using Microsoft Excel 2016 and Review Manager software version 5.3, respectively. Risk ratio and standard mean difference with 95% confidence interval (CI) of the outcomes were calculated as effect measure. The I² statistic was calculated for heterogeneity, as a measure of the proportion of the overall variation that is attributable to between-study heterogeneity. A fixed-effects (FE) model was used if I² < 50%; otherwise, the random-effects model was used.

To assess whether the results were influenced by study characteristics (effect modifiers), a subgroup analysis was conducted according to the study duration (<12 or ≥12 months). Additionally, sensitivity analyses were performed before combining RCTs and non-RCTs in the meta-analyses to determine possible additional sources of heterogeneity and changes in effect sizes.

Publication bias was tested by visual inspection of the funnel plots. When few studies are included in the analysis, the power of the tests is too low; therefore, publication bias was only examined if >10 study comparisons were included in the analysis [23].

3. Results

3.1. Study Characteristics. The search identified 6746 studies, of which 2157 were duplicates. Then, 4589 titles and abstracts were screened, with 145 studies for full-text screening. Finally, 18 eligible studies (911 participants) [24–41] evaluated the effects of intermittent or continuous VLEDs on overweight or obese patients with T2DM compared with other energy control methods, and specifically, 7 studies (583 participants) [25–31] compared VLEDs with LEDs, 6 studies (204 participants) [36–41] with MER, and 5 studies (124 participants) [24, 32–35] with bariatric surgery. Particularly, among the five studies involving surgical treatment, four studies (Jackness et al. [24], Lips et al. [32], Plum et al. [33], and Steven et al. [35]) used gastric bypass and 1 study (Cinkajzlova et al. [34]) used a variety of surgical approaches, including gastric plication (10 participants), gastric banding (2 participants), and gastric bypass (1 participant). Seven of the 18 included studies were non-RCTs. All of them were observational studies, four of them (Jackness et al. [24], Lips et al. [32], Plum et al. [33], and Cinkajzlova et al. [34]) compared VLEDs with bariatric surgery, and 3 of them (Paisey et al. [36–38]) compared VLEDs with MER. Figure 1 shows the screening process. Table 1 shows the main characteristics of included trials.

3.2. Evaluation of the Risk of Bias of the Selected Studies. The risk of bias for the included RCTs was assessed using the Cochrane risk of bias tool. None of the RCTs had an overall low risk of bias. Most RCTs had unclear risk of bias for sequence generation, allocation concealment, blinding of participants, blinding of outcome, and selective reporting because no detailed information was provided. However, three studies had high risk of bias for blinding of participants and blinding of outcome assessment, and one study had high risk of bias for allocation concealment because it could not be performed. Moreover, there is incomplete outcome data that most studies had a low risk of bias. Risk of bias assessment of included trials is shown in Figure 2.

The risk of bias for the included non-RCTs according to the ROBINS-I tool is presented in Figure 3. None of the studies had a low or moderate risk of bias, six (Jackness et al. [24], Lips et al. [32], Plum et al. [33], and Paisey et al. [36–38]) had signs of serious bias, and one (Cinkajzlova et al. [34]) had critical bias. The domain “bias due to confounding” was a main source of critical or serious risk of bias. The domain “bias in selection of participants into the study” had moderate or serious risk of bias in all studies. Risk of bias assessment is shown in Figure 3.

3.3. Meta-Analysis

3.3.1. Weight Loss

(1) VLEDs versus LEDs. Seven studies [25–31] analyzed weight loss when a VLED (n = 246) was compared with a LED (n = 241). Five of the studies provided data at the end of the intervention, and three provided data in the long-term follow-up (≥1 year). Subgroup analyses did result in differences in various time points. When the intervention is completed, the VLED group lost significantly more weight than the comparator arms (MD = −2.77; 95% CI = −4.81, −0.72; P = 0.008, <0.05; I² = 0%). However, when follow-up is ≥1 year, the observed difference in weight loss compared with controls was not significant (MD = −0.84; 95% CI = −3.01, 1.32; P = 0.45; I² = 0%) (Figure 4).

(2) VLEDs versus Bariatric Surgery. Four studies [24, 32, 33, 35] analyzed the weight loss between the VLED and surgery groups, including 84 participants. Moreover, the surgical methods used in these four studies were RYGB as comparator arms. The merged data with no evidence of interstudy heterogeneity (I² = 0%), according to the DerSimonian-Laird FE model, revealed that the VLEDs and RYGB have
similar effects on weight loss, and there is no significant difference between them (MD = 2.51; 95%CI = −9.52, 14.54; \(P = 0.37, >0.05\)) (Figure 5).

(3) VLEDs versus MER. Four studies [37–40] analyzed the weight loss when a VLED (\(n = 88\)) was compared with MER (\(n = 88\)). Three studies provided data at the end of the intervention, and one provided data for long-term follow-up (5 years). In particular, the study of Williams et al. [40] contains two types of VLED interventions, and that of Paisey et al. [38] contains data for two endpoints. According to the results of the subgroup analysis, the data at the end of the intervention showed that VLED was significantly better than MER in weight loss (MD = −6.72; 95%CI = −10.05, −3.39; \(P < 0.0001\)), with evidence of moderate heterogeneity \(\left(I^2 = 55\%; P_{\text{heterogeneity}} = 0.06\right)\). Sensitivity analysis showed that the heterogeneity was 0% when "Paisey et al. [38]" was removed, and the effect of VLEDs on weight loss was still significantly better than that of the control (MD = −5.19; 95%CI = −7.6, −2.78; \(P < 0.0001\)). However, when followed up for 5 years, similar to the result of the "Paisey et al. [37]" study, MER was better
| Study ID | Study type | Interventions (kcal/day)                                                                 | Comparator (kcal/day)                                                                 | Use of hypoglycemic drugs                                                                 | Study duration | Follow-up |
|----------|------------|----------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|----------------|-----------|
| Anderson 1994 | RCT        | VLED (800): at least five liquid supplements/day which provide 800 kcal with 80 g of high-quality protein+two vitamin/mineral tablets | LED (approximately 820): at least three supplements/day which provide 320 kcal and 32 g of high-quality protein, one vitamin/mineral tablet, recommended evening meal of approximately 500 kcal and 50 g of high-quality protein | Unclear                                                                                   | 3 months       | 1 year    |
| Carter 2016 | RCT        | Intermittent VLED (400-598): 1670-2500 kJ/day for 2 days each week, with the remaining 5 days as habitual eating | LED (1196-1555): continuous energy restriction diet of 5000-6500 kJ/day               | Medications adjusted according to blood glucose level                                         | 12 weeks       | None      |
| Carter 2018 | RCT        | VLED (500-600): an intermittent energy restriction diet (500-600 kcal/d) followed for 2 nonconsecutive days per week (participants followed their usual diet for the other 5 days) | LED (1200-1500): a continuous energy restriction diet (1200-1500kcal/d) followed for 7 days per week | Medications could be reduced depending on glucose                                            | 12 months      | 2 years   |
| Carter 2019 | RCT        | VLED (500-600): an intermittent energy restriction diet (500-600 kcal/d) followed for 2 nonconsecutive days per week (participants followed their usual diet for the other 5 days) | LED (1200-1500): a continuous energy restriction diet (1200-1500kcal/d) followed for 7 days per week | Medications could be reduced depending on glucose                                            | 12 months      | 2 years   |
| Harvey 1993 | RCT        | VLED (400-500): during weeks 1-12, consumed a 400-500 kcal/day. This was followed by a 6-week refeeding period, which required slow reintroduction of calories, carbohydrate, and fat. By the end of the 6 weeks of refeeding, subjects in the VLED were prescribed a self-selected balanced, low-calorie diet (1000-1200 kcal/day) | LED (1000-1200): a self-selected balanced diet of 1000-1200 kcal per day for 6 months | 15 of the subjects were treated with diet only, 54 with oral medication, and 23 with insulin. | 24 weeks       | None      |
| Wing 1991  | RCT        | VLED (400-500): weeks 0–4: 1000–1500 kcal/day; weeks 5–12: 400–500 kcal/day; weeks 13–20: 1000 kcal/day; weeks 21–72: 1000–1500 kcal/day (weight maintenance). Included a 20-week behavioural treatment programme with weekly group meetings including instructions on behavioural modification, exercise, and diet | LED (1000–1500): weeks 0–20: 1000–1500 kcal/day (intervention period); weeks 21–72: 1000–1500 kcal/day (weight maintenance). Included a 20-week behavioural treatment programme with weekly group meetings including instructions on behavioural modification, exercise, and diet | Unclear                                                                                   | 20 weeks       | 1 year    |
| Study ID | Study type | Interventions (kcal/day) | Comparator (kcal/day) | Use of hypoglycemic drugs | Study duration |
|----------|------------|--------------------------|-----------------------|---------------------------|---------------|
| Wing 1994 | RCT | VLED (400–500): weeks 0–12 and 24–36: 400–500 kcal/day; vitamins and supplements, otherwise 1000–1200 kcal/day. Included a 50-week behavioural treatment programme with weekly group meetings including instructions on behavioural modification, exercise, and diet | LED (1000–1200): weeks 0–48: 1000–1200 kcal/day (intervention period); subjects were encouraged to keep their fat intake below 30% of the daily calorie intake. Included a 50-week behaviour treatment programme with weekly group meetings including instructions on behavioural modification, exercise, and diet | Unclear | Unclear | 1 year | 2 years |
| Jackness 2013 | NRCT | VLED (300–500): day 1: 360 kcal/day; days 2–24: 500 kcal/day | RYGB (500): postoperative VLED is assumed of approximately 500 kcal/day until the end of week 3 | Unclear | Unclear | Mean study period of 21 days | None |
| Lips 2013 | NRCT | VLED: weeks 0–3: 600 kcal/day (intervention period); weeks 3–8: 800–1000 kcal/day; after 2 months: 1200 kcal/day | RYGB (<800): first 5 days after RYGB operation: <600 kcal/day; weeks 1–3: gradual increase to 700–800 kcal/day; week 3–month 3: 1200 kcal/day | Unclear | Unclear | 3 months | None |
| Plum 2011 | NRCT | VLED (800): the diet divided into five servings of 160 kcal (800 kcal/day) in 237 ml per serving | RYGB: postintervention, subjects followed dietary instructions provided by the surgical team | 55% reduction in the number of medications after LCD | Antidiabetic medications were discontinued after RYGB | VLED: 8.1 (0.5) weeks | RYGB: 3.4 (0.3) weeks | None |
| Cinkajlova 2018 | NRCT | VLED (595): total energy content of 2500 kJ/day for 3 weeks | Surgery: the procedures included gastric plication (10 subjects), gastric banding (2 subjects), and gastric bypass (1 subject) | Unclear | Unclear | VLCD 3 weeks; control 1 m, 3 m, and 1 y | None |
| Steven 2016 | RCT | VLED (700): the VLED provided an average of 700 kcal/day | RYGB (~800): the postoperative (RYGB) diet was water only on day 1 then a semisolid diet (~800 kcal/day) for the rest of the first week | Participants were asked to stop medications prior to the first study; metformin and/or sulphonylureas for at least 72 h, dipeptidyl peptidase-4 inhibitors for 1 month, and insulin for at least 24 h | Unclear | Unclear | 7 days | None |
Table 1: Continued.

| Study ID   | Study type | Interventions (kcal/day)                                                                 | Comparator (kcal/day)                                                                 | Use of hypoglycemic drugs                     | Study duration | Study duration Follow-up |
|------------|------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|---------------------------------------------|---------------|--------------------------|
| Paisey 1995 | NRCT       | VLED (400-670): 400-470 kcal/d for women, 540-670 kcal/d for men for 3-5 months and repeated in the course of the study if appropriate. Once an agreed target weight had been reached, patients were seen intensively to wean them back onto a low-fat diet. A standardized programme of low-fat, low-refined carbohydrate foods was introduced over a 6-week period as patients transferred from VLED to normal eating patterns. They were advised to continue low-fat nutrition in the long term with three main meals daily. MER: low-fat, low-sugar, and high-fibre intake advised; 5-day self-report food records were collected and discussed individually, repeated every 6-8 weeks. Aerobic exercises with encouragement performed at each visit followed by a group discussion on nutrition. All antidiabetic medication was stopped on day one, and insulin dosage halved. Hypotensive and hypolipidemic agents were stopped if appropriate at one month. | Unclear | 6 months | None |
| Paisey 1998 | NRCT       | Same as “Paisey 1995”                                                                 | Same as “Paisey 1995”                                                                 | Unclear | 12 months | None |
| Paisey 2002 | NRCT       | Same as “Paisey 1995”                                                                 | Antidiabetic and antihypertensive medications were stopped during the first week of treatment | Unclear | At least 6 weeks | 5 years |
| Li 2017     | RCT        | VLED (300): days 1–2: low-calorie diet (1200 kcal/day); from the evening of study day 3 to the evening of study day 11: 300 kcal/day; followed by 3 low-calorie diet days (1200 kcal/day), followed by advice about a Mediterranean diet. Fasting took place only once in the 4-month period. MER: follow the principles of a Mediterranean diet. | Subjects were advised to abstain from other new treatments against diabetes during the study period | Unclear | 4 months | None |
| Williams 1998 | RCT    | VLED (400-600): 1500-1800 kcal/day diet, except for a total of 20 study days during which they consumed a 400-600 kcal/day VLED. (1-day): a VLED for 5 consecutive days during week 2 of the study and then 1 day a week for 15 weeks, subjects used diaries to record daily caloric intake | MER (1500-1800): a 1500-1800 kcal/day diet throughout the 20 weeks of the treatment programme. Included a 20-week behavioural treatment programme with weekly group meetings including instructions on behavioural modification, exercise, and diet. Subjects used diaries to record daily caloric intake | Unclear | 20 weeks | None |
Table 1: Continued.

| Study ID  | Study type | Interventions (kcal/day)                                                                 | Comparator (kcal/day)                                                                 | Use of hypoglycemic drugs | Study duration | Study duration | Follow-up |
|-----------|------------|----------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|---------------------------|----------------|----------------|-----------|
| Williams  | RCT        | VLED (400-600): 1500-1800 kcal/day diet, except for a total of 20 study days during which they consumed a 400-600 kcal/day VLED. (5-day): a VLED for 5 consecutive days during weeks 2, 7, 12, and 17 and a 20-week behavioural treatment programme with weekly group meetings including instructions on behavioural modification, exercise, and diet. Subjects used diaries to record daily caloric intake. | MER (1500-1800): a 1500-1800 kcal/day diet throughout the 20 weeks of the treatment programme. Included a 20-week behavioural treatment programme with weekly group meetings including instructions on behavioural modification, exercise, and diet. Subjects used diaries to record daily caloric intake. | Unclear                | Unclear        | 20 weeks       | None      |
| Laakso    | RCT        | VLED (500-800): day 1–day 3: 30 kcal/kg/d; day 4–day 15: 500 kcal/d; day 15–day 17: 800 kcal/d | MER (30 kcal/kg/d): the diet was as previously described (30 kcal/kg/d) consisting of 50% carbohydrates, 30% fat, and 20% protein divided into three main meals. | All medications for diabetes were discontinued | Insulin was started using intermediate-acting insulin as one single injection at 7 AM. The mean dosage of insulin (+SEM) was 39 ± 5 U/d. | 2 weeks        | None      |

VLED: very low-energy diet; LED: low-energy diet; MER: mild energy restriction; RYGB: Roux-en-Y gastric bypass; RCT: randomized controlled trial; NRCT: nonrandomized controlled trial.
Figure 2: Risk of bias summary of included randomized trials with the Cochrane risk of bias tool.

Figure 3: Risk of bias summary of included nonrandomized trials with the ROBINS-I tool.

Figure 4: Forest plot on the mean difference in weight loss between VLED and LED controls.
3.3. Blood Glucose and Changes in Medication

(1) VLEDs versus LEDS. Four studies [25, 28, 30, 31] analyzed the blood glucose levels between the VLED and LED groups, and all of them provided data at the end of the intervention. Simultaneously, two provided data for long-term follow-up (>1 year). A significant difference in weight change in favor of the intervention arm was noted at both the end of the intervention (MD = −1.18; 95%CI = −2.05,−0.30; P = 0.008, <0.05) and follow-up (MD = −1.43; 95%CI = −2.65,−0.20; P = 0.02, <0.05), and both of them had no evidence of interstudy heterogeneity (I^2 = 0%). Regarding the use of hypoglycemic drugs, Carter et al. reported that although medication dose decreased with time, all participants using medication at baseline were also using medication at the end of the study. At 2 years, one study (Wing et al. [31]) reported that fewer participants in the VLED group required medication (45% vs. 69% in the VLED and LED groups, respectively) (Figure 7).

(2) VLEDs versus Bariatric Surgery. Five studies [24, 32–35] analyzed the blood glucose levels between the VLED (n = 69) and bariatric surgery groups (n = 55). The merged data with no evidence of interstudy heterogeneity (I^2 = 49%), according to the DerSimonian-Laird FE model, revealed that VLEDs and surgery have similar effects on weight loss, and there is no significant difference between them (MD = 0.37; 95%CI = −0.22, 0.96; P = 0.22, >0.05) (Figure 8). In the use of hypoglycemic drugs, one study [33] showed that all hypoglycemic drugs were discontinued in the RYGB arm and decreased by 55% in the VLED arm after the intervention. In another study [32], metformin was reintroduced in 4/15 participants in the RYGB arm and 2/12 participants in the VLED arm after the intervention, and the difference was not significant.

(3) VLEDs versus MER. Five studies [36, 37, 39–41] analyzed the blood glucose levels between the VLED (n = 86) and MER groups (n = 84). Results from the subgroup analyses showed that VLED was significantly better than MER in lowering blood glucose levels (MD = −6.72; 95%CI = −10.05,−3.39; P < 0.0001) at the end of the intervention, with evidence maintained than VLEDs (MD = 4.1; 95%CI = 0.13, 8.07; P = 0.06) (Figure 6).
of low heterogeneity ($I^2 = 48\%; P_{\text{heterogeneity}} = 0.17$). However, at the 5-year follow-up, only one study by “Paisey et al. [37]” reported that the difference in blood glucose levels compared with controls was not significant (MD = −1; 95%CI = −4.62, 2.62; $P = 0.59$). In the use of hypoglycemic drugs at the end of the intervention, the study of Paisey et al. showed that, at 6 months (all patients who underwent VLEDs had reverted to normal food for at least two weeks), the patients in the VLED group discontinued insulin, sulphonylureas, or hypolipidemic agents, while patients in the MER group were not able to discontinue their antidiabetic or hypolipidemic therapies. At 1 year, 14 of 15 patients in the VLED group, but none in the conventional diet group, had discontinued insulin and any oral hypoglycemic medication (Figure 9).

3.3.3. TG

(1) VLEDs versus LEDs. Four studies [25, 28, 30, 31] analyzed the TG level between the VLED ($n = 185$) and LED groups ($n = 179$). All studies provided data at the end of the intervention, and two provided data in the long-term follow-up ($\geq 1$ year). Results from subgroup analyses showed that the VLED group had significantly lower TG level than the comparator arms at the end of the intervention (MD = −0.35; 95%CI = −0.58, −0.12; $P = 0.002$, <0.05; $I^2 = 38\%$). However, when the follow-up duration is $\geq 1$ year, the observed difference in the TG level compared with controls was not significant (MD = −0.25; 95%CI = −0.55, 0.06; $P = 0.12$, >0.05; $I^2 = 0\%$) (Figure 10).

(2) VLEDs versus Bariatric Surgery. Four studies [24, 33–35] analyzed the TG levels between the VLED ($n = 57$) and bariatric surgery groups ($n = 40$). The merged data, which had no evidence of interstudy heterogeneity ($I^2 = 2\%$), according to the DerSimonian-Laird FE model, revealed that VLEDs and surgery have similar effects on weight loss, and there is no significant difference between them (MD = −0.3; 95%CI = −0.74, 0.17; $P = 0.7$, >0.05) (Figure 11).

(3) VLEDs versus MER. Four studies [37–40] analyzed the TG levels between the VLED ($n = 88$) and MER groups ($n = 84$). Results from subgroup analyses showed that a VLED was significantly better than MER in lowering TG levels (MD = −0.55; 95%CI = −0.93, −0.17; $P = 0.005$, <0.05) at the end of the intervention, with no evidence of interstudy

| Study or subgroup | Experimental Mean | SD | Total | Control Mean | SD | Total | Weight | Mean difference IV, fixed, 95% CI | Mean difference IV, fixed, 95% CI |
|------------------|-------------------|----|-------|--------------|----|-------|--------|--------------------------------|--------------------------------|
| Anderson 1994    | 7.6               | 2.24| 20    | 8.9          | 3.49| 19    | 14.8%  | −1.30 [−3.15, 0.55]              |                                |
| Wing 1991        | 7.7               | 2.1| 17    | 9.3          | 1.7 | 16    | 30.0%  | −1.60 [−2.90, −0.30]             |                                |
| Wing 1994        | 9.28              | 3.67| 38    | 9.78         | 3.28| 41    | 21.4%  | −0.50 [−2.04, 1.04]              |                                |
| Subtotal (95% CI) |                   |    |       |              |    |       |        | −1.18 [−2.05, −0.30]             |                                |

Heterogeneity: chi² = 1.17, df = 2 ($P = 0.56$); $I^2 = 0\%$

Test for overall effect: $Z = 2.64$ ($P = 0.008$)

| Study or subgroup | Experimental Mean | SD | Total | Control Mean | SD | Total | Weight | Mean difference IV, fixed, 95% CI | Mean difference IV, fixed, 95% CI |
|------------------|-------------------|----|-------|--------------|----|-------|--------|--------------------------------|--------------------------------|
| Carter 2019      | 8.1               | 4.36| 59    | 8.5          | 4.97| 51    | 16.4%  | −0.40 [−2.16, 1.36]             |                                |
| Wing 1991a       | 10.4              | 4.1 | 17    | 13.5         | 3.2 | 16    | 8.1%   | −3.10 [−5.60, −0.60]            |                                |
| Wing 1994a       | 11.01             | 4.84| 36    | 12.79        | 5.35| 37    | 9.3%   | −1.78 [−4.12, 0.56]             |                                |
| Subtotal (95% CI)|                   |    |       |              |    |       |        | −1.43 [−2.65, −0.20]            |                                |

Heterogeneity: chi² = 1.11, df = 2 ($P = 0.21$); $I^2 = 36\%$

Test for overall effect: $Z = 2.28$ ($P = 0.02$)

| Study or subgroup | Experimental Mean | SD | Total | Control Mean | SD | Total | Weight | Mean difference IV, fixed, 95% CI | Mean difference IV, fixed, 95% CI |
|------------------|-------------------|----|-------|--------------|----|-------|--------|--------------------------------|--------------------------------|
| Cinkajzlová 2018 | 7.31              | 2.6 | 27    | 6.47         | 1.9 | 13    | 17.1%  | 0.84 [−0.58, 2.26]              |                                |
| Jackness 2013    | 6.11              | 1.25| 14    | 6.94         | 2.21| 11    | 16.3%  | −0.83 [−2.29, 0.63]            |                                |
| Lips 2013        | 5.9               | 1   | 12    | 5.8          | 1.2 | 15    | 50.4%  | 0.10 [−0.73, 0.93]             |                                |
| Plum 2011        | 8.17              | 2.06| 7     | 6.44         | 1.18| 7     | 11.2%  | 1.73 [−0.03, 3.49]             |                                |
| Steven 2016      | 9.4               | 3.6 | 9     | 7.1          | 1.8 | 9     | 5.0%   | 2.30 [−0.33, 4.93]            |                                |
| Total (95% CI)   |                   |    |       |              |    |       |        | 0.37 [−0.22, 0.96]             |                                |

Heterogeneity: chi² = 7.78, df = 4 ($P = 0.10$); $I^2 = 49\%$

Test for overall effect: $Z = 1.23$ ($P = 0.22$)
3.2.1 End of intervention

| Study or subgroup | Experimental Mean (SD) | Control Mean (SD) | Weight | Mean difference IV, fixed, 95% CI |
|-------------------|------------------------|------------------|--------|----------------------------------|
| Laasko 1988       | 9.6 (1.4)              | 8.5 (1.91)       | 7      | -1.10 [−0.61, 2.81]              |
| Li2017            | 7.89 (1.58)            | 8.39 (1.59)      | 16     | -0.50 [−1.60, 0.60]              |
| Paisley 1998      | 11.3 (8.1)             | 13.2 (5.8)       | 15     | -1.90 [−6.94, 3.14]              |
| Williams 1998     | 7.6 (2.8)              | 9.4 (2.1)        | 17     | 1.91 [−3.46, 0.14]               |
| Williams 1998a    | 7.8 (2.3)              | 9.4 (2.1)        | 17     | 22.2% [−3.06, −0.14]             |
| Subtotal (95% CI) | 74                     | 72               | 96.4%  | -0.74 [−1.44, −0.04]             |

Heterogeneity: $\chi^2 = 7.73$, df = 4 ($P = 0.10$); $I^2 = 48$
Test for overall effect: $Z = 2.08$ ($P = 0.04$)

3.2.2 Follow-up 5 years

| Study or subgroup | Experimental Mean (SD) | Control Mean (SD) | Weight | Mean difference IV, fixed, 95% CI |
|-------------------|------------------------|------------------|--------|----------------------------------|
| Paisley 2002      | 13 (5)                 | 14 (4)           | 12     | 3.6% [−1.00, 2.62]               |
| Subtotal (95% CI) | 12                     | 12               | 3.6%   | -1.00 [−4.62, 2.62]              |

Heterogeneity: Not applicable
Test for overall effect: $Z = 0.54$ ($P = 0.59$)
Test for subgroup differences: $\chi^2 = 0.02$, df = 1 ($P = 0.89$); $I^2 = 0$

Total (95% CI) 86 84 100.0% [−1.44, −0.06]

Figure 9: Forest plot on the mean difference in blood glucose levels between VLED and MER controls.

3.4.1 End of intervention

| Study or subgroup | Experimental Mean (SD) | Control Mean (SD) | Weight | Mean difference IV, fixed, 95% CI |
|-------------------|------------------------|------------------|--------|----------------------------------|
| Anderson 1994     | 1.7 (0.89)             | 2 (0.87)         | 19     | 10.8% [−0.30, −0.85]             |
| Wing 1991         | 1.02 (0.32)            | 1.61 (0.65)      | 16     | 26.5% [−0.59, −0.94]             |
| Wing 1994         | 1.45 (0.67)            | 1.59 (0.89)      | 41     | 27.6% [−0.14, −0.49]             |
| Subtotal (95% CI) | 75                     | 76               | 65.0%  | −0.35 [−0.58, −0.12]            |

Heterogeneity: $\chi^2 = 3.22$, df = 2 ($P = 0.20$); $I^2 = 38$
Test for overall effect: $Z = 3.05$ ($P = 0.002$)
Test for subgroup differences: $\chi^2 = 0.02$, df = 1 ($P = 0.89$); $I^2 = 0$

Total (95% CI) 185 178 100.0% [−0.50, −0.13]

Figure 10: Forest plot on the mean difference in TG levels between VLED and LED controls.

heterogeneity ($I^2 = 23%$; $P_{\text{heterogeneity}} = 0.25$). However, at the 5-year follow-up, similar to the result of the “Paisley et al. [37]” study, the difference in lowering TG level compared with controls was not significant (MD = 0.4; 95% CI = −1.11, 1.91; $P = 0.60$) (Figure 12).

3.3.4. HOMA-IR. Four studies [24, 32−34] analyzed the change in HOMA-IR between the VLED (n = 60) and bariatric surgery groups (n = 46), and one study analyzed the change in HOMA-IR between the VLED (n = 75) and MER groups (n = 76). The meta-analysis showed that there was no significant difference between VLEDs and surgery in increasing HOMA-IR (MD = −1; 95%CI = −2.7, 0.7; $P = 0.25, >0.05$) (Figure 13). Additionally, one study (Li et al. [39]) reported that nonsignificant improvements in HOMA-IR were also observed between the VLED and MER groups.

3.3.5. Dropout. Comparing the VLED and bariatric surgery groups, no loss of patients was reported. However, most studies on VLEDs compared with those on LEDs or MER reported increased dropout rate.

(1) VLEDs versus LEDs. Six studies [25−28, 30, 31] reported the difference in dropout rate between the VLED (n = 253) and LED groups (n = 253). The meta-analyses showed that the VLED group had a similar dropout rate with the comparator arms (OR = 0.74; 95%CI = 0.49, 1.13; $P = 0.16, >0.05$; $I^2 = 0$) (Figure 14).
3.3.6. Side Effects. Nine of 18 studies involved reports of adverse reactions. Adverse reactions reported by Carter et al. [26, 27] were mainly hypoglycemia, hyperglycemia, and headache. Paisey et al. [36–38] reported adverse reactions such as hypoglycemia, myocardial infarction, and telogen effluvium. Wing et al. [30, 31] mainly reported adverse reactions such as cold intolerance, constipation, and hair loss. Anderson’s study showed that frequently reported side effects during the weight loss phase included constipation, diarrhea, dizziness, and fatigue. The adverse reactions reported in Li et al.’s study were slight headache and dizziness during energy restriction. None of these studies reported significant differences in side effects between the VLED and control groups (see Table 2 for details).

(2) VLEDs versus MER. Five studies [36, 37, 39–41] reported the difference in dropout rates between the VLED (n = 97) and MER groups (n = 97). Results from the meta-analyses showed that the VLED group had a similar dropout rate with the MER group (OR = 0.68; 95% CI = 0.32, 1.48; P = 0.33, >0.05) with no evidence of interstudy heterogeneity (I² = 0%; P heterogeneity = 0.93) (Figure 15).
although initial weight losses were greater in the VLED of glycemic control had returned to baseline, and no di
follow-up. Moreover, at one-year assessment, the measures
than those in the behavioural therapy group in 1 year of
months. Paisey et al. [37] found that weight loss was slower
increased by 0.3% (3.3 mmol/mol) from baseline at 24
and 24 months. In this follow-up study, HbA1c level had
participants regained 33% of their weight losses between 12
low-up, 44 (52%) regained weight (>
24 months, in the completer analysis of 84 participants at fol-
energy restriction therapy. One study [28] reported that at
higher than those in the intensive conventional diet group than in the VLED
3.3.7. Rebound. Only three studies mentioned a rebound in
body weight, blood glucose level, and other indicators after
energy restriction therapy. One study [28] reported that at
24 months, in the completer analysis of 84 participants at fol-
up, 44 (52%) regained weight (>1 kg weight gain) and
participants regained 33% of their weight losses between 12
and 24 months. In this follow-up study, HbA1c level had
increased by 0.3% (3.3 mmol/mol) from baseline at 24
months. Paisey et al. [37] found that weight loss was slower
in the intensive conventional diet group than in the VLED
group but better maintained at 5 years: group 1, 4.8 ± 6 kg,
and group 2, 8.9 ± 4 kg. Wing et al. [30, 31] reported that,
although initial weight losses were greater in the VLED
group, these participants regained significantly more weight
than those in the behavioural therapy group in 1 year of
follow-up. Moreover, at one-year assessment, the measures
of glycemic control had returned to baseline, and no differ-
ces were observed between treatment groups.

3.4. Publication Bias. All outcome indicators were analyzed in <10 studies, so publication bias was not examined.

3.5. GRADE for the Outcomes. We evaluated all outcome indicators by GRADE profiler 3.6 from the following aspects: (1) downgrade quality of evidence, risk of bias, inconsistency, indirectness, imprecision, and publication bias and (2) upgrade quality of evidence, large effect, plausible confounding changing the effect, and dose-response gradient.

After a comprehensive analysis, the evidentiary body was formed and found that all outcome indicators had low quality or extremely low quality (see Tables 3–5 for details).

4. Discussion

Our systematic review provides evidence based on current clinical trials on the efficacy of continuous and intermittent VLEDs in overweight and obese individuals with T2DM by comparison to other methods of energy restriction. First, during the intervention period, a VLED is superior in the reduction of body weight and blood glucose and TG levels to LEDs and MER. After long-term follow-up, there is no obvious difference in weight loss between VLEDs and LEDs, but glycemic control is still more effective in VLEDs. Second, VLEDs offer beneficial effects on weight loss, glycemic control, and improvement of insulin resistance comparable to bariatric surgery.

Increasing evidence suggested that modest and sustained weight loss improved glycemic control in overweight and obese individuals with T2DM [3]. Furthermore, recent studies reported that intentional weight losses by low-calorie diets, usually >15 kg, could reverse T2DM into a nondiabetic state [5, 42]. Based on the current studies, our study concluded that more extreme dietary energy restriction with

| Study or subgroup | Experimental Events | Control Events | Weight | Odds ratio M-H, fixed, 95% CI | Odds ratio M-H, fixed, 95% CI |
|------------------|------------------|---------------|--------|-------------------------------|-------------------------------|
| Anderson 1994    | 0                | 20            | 1      | 2.8%                          | 0.32 [0.01, 8.26]            |
| Carter 2016      | 5                | 31            | 7      | 32.7%                         | 0.69 [0.19, 2.45]            |
| Carter 2018      | 20               | 70            | 23     | 29.8%                         | 0.77 [0.37, 1.58]            |
| Carter 2019      | 28               | 70            | 25     | 6.3%                          | 0.13 [0.01, 2.81]            |
| Wing 1991        | 0                | 17            | 3      | 17.2%                         | 0.37 [0.11, 1.28]            |
| Wing 1994        | 4                | 45            | 10     |                                |                               |
| Total (95% CI)   | 253              |               | 253    | 100.0%                        | 0.74 [0.49, 1.13]            |

**Figure 14:** Forest plot of dropout rates between VLED and LED controls.

| Study or subgroup | Experimental Events | Control Events | Weight | Odds ratio M-H, fixed, 95% CI | Odds ratio M-H, fixed, 95% CI |
|------------------|------------------|---------------|--------|-------------------------------|-------------------------------|
| Laakso 1998      | 0                | 8             | 1      | 9.0%                          | 0.29 [0.01, 8.37]            |
| Li 2017          | 7                | 23            | 7      | 30.9%                         | 1.00 [0.28, 3.51]            |
| Paisey 1998      | 0                | 15            | 0      | Not estimable                 |                               |
| Paisey 2002      | 2                | 15            | 3      | 16.5%                         | 0.62 [0.09, 4.34]            |
| Williams 1998    | 2                | 18            | 4      | 22.5%                         | 0.44 [0.07, 2.76]            |
| Williams 1998a   | 3                | 18            | 4      | 21.1%                         | 0.70 [0.13, 3.70]            |
| Total (95% CI)   | 97               |               | 97     | 100.0%                        | 0.68 [0.32, 1.48]            |

**Figure 15:** Forest plot of dropout rate between VLED and MER controls.
VLEDs is an effective method to achieve intensive weight loss in a short term and improve glycemic control more effectively compared with LEDs and MER. This conclusion supported the recommendation of the American Diabetes Association (ADA) Standards of Medical Care in Diabetes that high-intensity diet intervention, physical activity, and behavioural therapies to achieve a 500-calorie deficit and maintain >5% weight loss should be prescribed for patients with type 2 diabetes who are overweight or obese and ready to achieve weight loss. Furthermore, previous studies showed that rapid weight loss by VLEDs is inevitably followed by weight regain [42], but recent studies with at least 1-year follow-up found that VLEDs might present a longer effect on weight maintenance [5, 43]. Another study showed that even though weight was regained, the short-term weight loss had long-lasting benefits on glycemic control and prevention of cardiovascular effects in T2DM [44]. Our results are in line with this study. After further analysis of the effects of long-term follow-up (1–5 years), we found no obvious difference in weight loss between VLEDs and LEDs, but VLEDs still maintained better glycemic control. The lasting effects of VLEDs may be attributed to improved insulin sensitivity remaining from weight loss [45], “metabolic memory” from the treatment period [46], and “legacy effect” by lifestyle intervention [47].

It is reported that dyslipidemia, especially hypertriglyceridermia, is an independent risk factor in predicting the development of diabetes, which is partially mediated by insulin resistance and obesity [48]. Several prospective studies have demonstrated that weight loss induced decreases in pancreatic and liver TG levels in T2DM, which was associated with the recovery of insulin secretory function [6, 49]. However, the effect of weight loss by VLEDs on the plasma TG level is rarely discussed. Our meta-analyses found that VLEDs reduced the plasma TG level in T2DM more effectively compared to LEDs and MER and had an equivalent effect of weight loss by VLEDs on the plasma TG level in T2DM, which was associated with the recovery of insulin secretory function [6, 49].

Additionally, VLEDs have lower costs and lesser adverse effects compared with bariatric surgery. Thus, VLEDs may be a considerable therapy when patients could not or would not wish to undergo surgical treatments. VLEDs are as effective as bariatric surgery (mainly RYGB) in terms of weight loss, glycemic control, insulin resistance improvement, and plasma TG level reduction. Additionally, VLEDs have lower costs and lesser adverse effects compared with bariatric surgery. Thus, VLEDs may be a considerable therapy when patients could not or would not wish to undergo surgical treatments.

VLEDs were found to be acceptable as indicated by the low dropout rate in both this and a previous study. The main reason may be that rapid weight loss increases patient’s confidence, and hunger of patients after VLED intervention is more inhibited. A study shows that attrition was lower when

### Table 2: Side effects.

| Study ID     | VLED                                     | Control                                      |
|--------------|------------------------------------------|----------------------------------------------|
| Carter 2016  | Hypoglycemia (<4 mmol/l) only occurred in insulin-controlled participants (n = 6), with no difference between treatment groups | Hypoglycemia (n = 6) |
| Carter 2018  | Hyperglycemia (n = 3)                     | Hyperglycemia (n = 7)                        |
| Paisey 1995  | Severe hypoglycemic attack (n = 1)       | Myocardial infarction (n = 1)                |
| Paisey 1998  | Nonfatal myocardial infarction (n = 1)   | Nonfatal myocardial infarction (n = 1)       |
| Paisey 2002  | Nonfatal myocardial infarction (n = 1)   | Primary biliary cirrhosis (n = 1)            |
| Wing 1991    | Coldness, constipation, dry skin, diarrhea, dizziness, vomiting, or weakness—commonly reported side effects of VLEDs. There were no significant differences over time in any of these symptoms and no significant difference between subjects in the LED and VLED groups. However, uric acid increased significantly in the VLED group | Unclear                                      |
| Wing 1994    | Common side effects included cold intolerance, constipation, and hair loss, which all resolved when the VLED was terminated | Frequently reported side effects during the weight loss phase included constipation (56% of subjects), diarrhea (31%), dizziness (31%), fatigue (31%), flu/sore throat (13%), headache (10%), vomiting (10%), blurred vision (10%), muscle cramps (8%), and syncope (5%). None of these side effects required treatment alteration. |
| Andorson 1994 | Telogen effluvium (n = 6, which recovered within 2 years of stopping VLEDs in five) | No serious adverse effects. Willingness to continue with treatment was 100% in both groups | No serious adverse effects |
| Li 2017      | No serious adverse effects: slight headache (n = 3); slight dizziness (n = 1) | No serious adverse effects |

VLED: very low-energy diet; LED: low-energy diet.
| Quality assessment | No. of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | No. of patients | Effect | Absolute | Quality | Importance |
|--------------------|---------------|--------|--------------|---------------|--------------|-------------|----------------------|----------------|--------|----------|---------|------------|
| Weight (better indicated by lower values) | 8 | Randomized trials | Serious | No serious inconsistency | Serious | No serious imprecision | None | 246 241 | — | MD -1.86 lower (-3.34 to -0.37 lower) | Low | 9 |
| Weight: end of the intervention (better indicated by lower values) | 5 | Randomized trials | Serious | No serious inconsistency | Serious | No serious imprecision | None | 151 146 | — | MD -2.77 lower (-4.81 to -0.72 lower) | Low | 9 |
| Weight: follow-up ≥ 1 year (better indicated by lower values) | 3 | Randomized trials | Serious | No serious inconsistency | Serious | No serious imprecision | None | 95 95 | — | MD -0.84 lower (-3.01 lower to 1.32 higher) | Very low | 9 |
| Glucose (better indicated by lower values) | 6 | Randomized trials | Serious | No serious inconsistency | Serious | No serious imprecision | None | 187 180 | — | MD -1.26 lower (-1.97 to -0.55 lower) | Low | 8 |
| Glucose: end of the intervention (better indicated by lower values) | 3 | Randomized trials | Serious | No serious inconsistency | Serious | No serious imprecision | None | 75 76 | — | MD -1.18 lower (-2.05 to -0.3 lower) | Low | 8 |
| Glucose: follow-up ≥ 1 year (better indicated by lower values) | 3 | Randomized trials | Serious | No serious inconsistency | Serious | No serious imprecision | None | 112 104 | — | MD -1.43 lower (-2.65 to -0.2 lower) | Very low | 8 |
| TG (better indicated by lower values) | 6 | Randomized trials | Serious | No serious inconsistency | Serious | No serious imprecision | None | 185 179 | — | MD 0.31 lower (-0.5 to -0.13 lower) | Low | 7 |
| TG: end of the intervention (better indicated by lower values) | 3 | Randomized trials | Serious | No serious inconsistency | Serious | No serious imprecision | None | 75 76 | — | MD -0.35 lower (-0.58 to -0.12 lower) | Low | 7 |
| TG: follow-up ≥ 1 year (better indicated by lower values) | 3 | Randomized trials | Serious | No serious inconsistency | Serious | No serious imprecision | None | 110 103 | — | MD -0.25 lower (-0.55 lower to 0.06 higher) | Very low | 7 |

Dropout

| | 6 | Randomized trials | Serious | No serious inconsistency | Serious | No serious imprecision | None | 57/253 (22.5%) 69/253 (27.3%) | OR 0.74 (0.49 to 1.13) | 56 fewer per 1000 (from 118 fewer to 25 more) | Low | 6 |

*CI: confidence interval; OR: odds ratio. GRADE Working Group grades of evidence: high quality: further research is very unlikely to change our confidence in the estimate of effect; moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate; low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate; very low quality: we are very uncertain about the estimate. 1There are studies that do not account for specific stochastic methods, so they are reduced by one level. 2Interventions include continuous VLEDs and intermittent VLEDs, which differ to some extent, so they are reduced by one level. 3No explanation was provided. 4The ratio of 95% CI to the effect is more than 50%. 95% CI is wider and its accuracy is poor, so it decreases one level.
| Quality assessment | No. of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | VLED | Bariatric surgery | Relative (95% CI) | Effect | Absolute | Quality | Importance |
|--------------------|---------------|--------|--------------|---------------|--------------|-------------|---------------------|------|-----------------|-----------------|--------|-----------|---------|------------|
| Weight             | 4             | Randomized trials | Serious¹ | No serious inconsistency | No serious indirectness | Serious² | None | 42 | 42 | MD -3.14 lower (-10.04 lower to 3.67 higher) | Low | 9 |
| Glucose (better indicated by lower values) | 5 | Randomized trials | Serious¹ | No serious inconsistency | No serious indirectness | Serious² | None | 69 | 55 | MD 0.37 higher (-0.22 lower to 0.96 higher) | Low | 8 |
| TG (better indicated by lower values) | 4 | Randomized trials | Serious¹ | No serious inconsistency | No serious indirectness | Serious² | None | 57 | 40 | MD -0.04 lower (-0.25 lower to 0.17 higher) | Low | 7 |
| HOMA-IR (better indicated by lower values) | 4 | Observational studies³ | No serious risk of bias | No serious indirectness | Serious² | None | 60 | — | — | MD -1 lower (-2.7 lower to 0.7 higher) | Very low | 6 |

**CI: confidence interval; OR: odds ratio. GRADE Working Group grades of evidence: high quality: further research is very unlikely to change our confidence in the estimate of effect; moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate; low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate; very low quality: we are very uncertain about the estimate. Some studies were nonrandomized controlled trials. The ratio of 95% CI to the effect is more than 50%. 95% CI is wider and its accuracy is poor, so it decreases one level. Case-control. The I² value of the combined results is larger, and there is statistical heterogeneity, so it falls by one grade.
| Quality assessment | No. of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | No. of patients | Mild energy restriction | Relative (95% CI) | Effect | Quality | Importance |
|--------------------|----------------|--------|--------------|---------------|--------------|-------------|----------------------|----------------|------------------------|----------------|---------|---------|------------|
| Weight (better indicated by lower values) | 6 | Randomized trials | Very serious | Serious | Serious | No serious imprecision | None | 88 | 88 | — | MD -4.57 lower (-9.44 lower to 0.3 higher) | Very low | 9 |
| Weight: end of the intervention (better indicated by lower values) | 5 | Randomized trials | Very serious | Serious | Serious | No serious imprecision | Strong association | 75 | 76 | — | MD -6.72 lower (-10.05 to -3.39 lower) | Very low | 9 |
| Weight: follow-up 5 years (better indicated by lower values) | 1 | Observational studies | Serious | No serious inconsistency | No serious indirectness | Serious | None | 13 | 12 | — | MD 4.1 higher (0.13 to 8.07 higher) | Very low | 9 |
| Glucose (better indicated by lower values) | 6 | Randomized trials | Very serious | No serious inconsistency | Serious | No serious imprecision | None | 86 | 84 | — | MD -0.75 lower (-1.44 to -0.06 lower) | Very low | 8 |
| Glucose: end of the intervention (better indicated by lower values) | 5 | Randomized trials | Very serious | No serious inconsistency | Serious | No serious imprecision | None | 74 | 72 | — | MD -0.74 lower (-1.44 to -0.04 lower) | Very low | 8 |
| Glucose: follow-up 5 years (better indicated by lower values) | 1 | Observational studies | Serious | No serious inconsistency | No serious indirectness | Serious | None | 12 | 12 | — | MD -1 lower (-4.62 lower to 2.62 higher) | Very low | 8 |
| TG (better indicated by lower values) | 6 | Randomized trials | Very serious | No serious inconsistency | Serious | No serious imprecision | None | 88 | 84 | — | MD -0.49 lower (-0.86 to -0.12 lower) | Very low | 7 |
| TG: end of the intervention (better indicated by lower values) | 5 | Randomized trials | Very serious | No serious inconsistency | Serious | No serious imprecision | None | 75 | 72 | — | MD -0.55 lower (-0.93 to -0.17 lower) | Very low | 7 |
| TG: follow-up 5 years (better indicated by lower values) | 1 | Observational studies | Serious | No serious inconsistency | No serious indirectness | No serious consideration | None | 13 | 12 | — | MD 0.4 higher (-1.11 lower to 1.91 higher) | Very low | 7 |
| Dropout | 6 | Randomized trials | Very serious | No serious inconsistency | No serious indirectness | No serious imprecision | None | 14/97 (14.4%) | 19/97 (19.6%) | OR 0.68 (0.32 to 1.48) | 54 fewer per 1000 (from 124 fewer to 69 more) | Low | 6 |

* CI: confidence interval; OR: odds ratio. GRADE Working Group grades of evidence: high quality: further research is very unlikely to change our confidence in the estimate of effect; moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate; low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate; very low quality: we are very uncertain about the estimate. ¹Some studies were nonrandomized controlled trials. ²There are studies that do not account for specific stochastic methods, so they are reduced by one level. ³The I² value of the combined results is larger and there is statistical heterogeneity, so it falls by one grade. ⁴Interventions include continuous VLEDs and intermittent VLEDs, which differ to some extent, so they are reduced by one level. ⁵After merger, the effect is large and the accuracy is high, so it goes up one level. ⁶Failure to adequately control confounding factors. ⁷The ratio of 95% CI to the effect is more than 50%, 95% CI is wider and its accuracy is poor, so it decreases one level. ⁸Case-control.
weight loss was undertaken rapidly rather than gradually, because rapid weight loss might motivate participants [52]. Moreover, ketosis suppresses appetite and increases the satiety hormone cholecystokinin, which increases the possibility that participants with rapid weight loss might have been less hungry during the weight loss phase than those following the gradual diet [53–56]. Of note, the experience of healthcare professionals involved in the trial in obesity treatment also had a significant impact on attrition.

While the short-term efficacy of VLEDs is evident and patient compliance is acceptable according to our analysis, the reports of adverse reactions in the studies are incomplete, limiting the use of this method.

In a previous systematic review, Rehackova et al. [19] revealed that VLEDs led to considerable weight loss and blood glucose control via small sample or qualitative studies. However, evidence on the long-term efficacy of VLEDs with regard to weight loss in individuals with T2DM is lacking. Our study has expanded the sample size and further analyzed the follow-up results between VLEDs and LEDs. After the follow-up (1–5 years), VLEDs present a more effective glycemic control effect, but there is no obvious difference in weight loss between VLEDs and LEDs. Some included studies [28, 30, 31, 37] also showed that, at the end of VLED intervention, the decrease in body weight, blood glucose level, and other indicators would rebound to varying degrees. This shows that adherence to a VLED regimen is crucial in maximizing intervention effects. It has been shown that greater initial weight loss facilitates weight maintenance if followed by an effective weight loss maintenance programme [57]. Further exploring a strategy to suppress hunger after rapid weight loss and prevent weight regain of VLEDs is greatly important in the popularization of this method.

This meta-analysis provides some objective evidence for the application of VLEDs in obese individuals with T2DM, but there are still many limitations in the study. First, both non–RCTs and RCTs were combined in the meta-analyses, which increased the heterogeneity and risk of bias. Therefore, the results of this study still need to be confirmed by high-quality research. Second, some high-quality research in this field has been conducted by a small number of research groups, resulting in insufficient representation of data. Thus, more extensive studies are needed to clarify the practicability of VLEDs in different ethnic groups. Third, most included studies did not mention the use of hypoglycemic drugs in participants. When VLEDs are used to intervene with obese patients with T2DM, determination of hypoglycemic drugs is difficult. In the future, the standardized research of this area should be strengthened. Lastly, only a few included studies that recorded follow-up results, which led to insufficient convincing evidence. Moreover, the longest follow-up duration in the included studies was only 5 years, so the long-term effect of VLEDs needs further study.

5. Conclusions

Dietary intervention through VLEDs is more effective in rapid weight loss and glycemic control and improved lipid metabolism in overweight and obese individuals with T2DM than LEDs and MER, although they have similar long-term effects. Moreover, VLEDs have similar efficacy and acceptability with bariatric surgery, which shows that VLEDs have considerable curative effect for remission of T2DM. However, after GRADE, it was found that all outcome indicators had low quality or base quality, so the results of this study still need to be further confirmed by high-quality research.

Abbreviations

DM: Diabetes mellitus
VLED: Very low-energy diet
LED: Low-energy diet
MER: Mild energy restriction
RYGB: Roux-en-Y gastric bypass
CI: Confidence interval
MD: Mean difference

Conflicts of Interest

The authors declare that they have no competing interests.

Authors’ Contributions

All authors take responsibility for the integrity of the data and the accuracy of data analysis. WJ. Liu and YN. Liu contributed to the study concept and design. YS. Huang and QY. Zheng developed the protocol design. YS. Huang, XW Fu, XQ. Zheng, CH. Xia, ZB. Zhu, and QY. Zheng carried out literature retrieval and data extraction. HS. Yang and QY. Zheng performed the statistical analysis. QY. Zheng, XQ. Zhang, and WJ. Liu performed the interpretation of data. YS. Huang and QY. Zheng are responsible for the drafting of the manuscript. HS. Yang, QY. Zheng, XQ. Zhang, WJ. Liu, and YN. Liu carried out quality assessment. WJ. Liu and YN. Liu contributed to critical revision of the manuscript. HS. Yang, WJ. Liu, and YN. Liu are responsible for technical support. All authors have read and agreed to the submission to this journal of the manuscript. Yi Shan Huang and Qiyan Zheng contributed equally to this work.

Acknowledgments

This study was supported by the National Natural Science Foundation of China (Grant Nos. 81570656 and 81774278) and the Initial Scientific Research Fund of Talent Introduction in Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine (2016TSRC).

References

[1] M. Bluher, “Obesity: global epidemiology and pathogenesis,” Nature Reviews Endocrinology, vol. 15, no. 5, article 176, pp. 288–298, 2019.
[2] C. Daousi, I. F. Casson, G. V. Gill, I. A. MacFarlane, J. P. Wilding, and J. H. Pinkney, “Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors,” Postgraduate Medical Journal, vol. 82, no. 966, pp. 280–284, 2006.
[3] American Diabetes Association, “8. Obesity management for the treatment of type 2 Diabetes:Standards of medical care in diabetes-2019,” Diabetes Care, vol. 42, Supplement 1, pp. S81–S89, 2019.

[4] American Diabetes Association, “4. Lifestyle Management:Standards of medical care in diabetes-2018,” Diabetes Care, vol. 41, Supplement 1, pp. S38–S50, 2018.

[5] M. E. Lean, W. S. Leslie, A. C. Barnes et al., “Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial,” Lancet, vol. 391, no. 10120, pp. 541–551, 2018.

[6] E. L. Lim, K. G. Hollingsworth, B. S. Arbisala, M. J. Chen, J. C. Mathers, and R. Taylor, “Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol,” Diabetologia, vol. 54, no. 10, pp. 2506–2514, 2011.

[7] M. L. Gow, L. A. Baur, N. A. Johnson, C. T. Cowell, and S. P. Garnett, “Reversal of type 2 diabetes in youth who adhere to a very-low-energy diet: a pilot study,” Diabetologia, vol. 60, no. 3, pp. 406–415, 2017.

[8] H. M. Parretti, S. A. Jebb, D. J. Johns, A. L. Lewis, A. M. Christian-Brown, and P. Aveyard, “Clinical effectiveness of very-low-energy diets in the management of weight loss: a systematic review and meta-analysis of randomized controlled trials,” Obesity Reviews, vol. 17, no. 3, pp. 225–234, 2016.

[9] R. L. Atkinson, W. H. Dietz, J. P. Foreyt et al., “Very low-calorie diets. National Task Force on the Prevention and Treatment of Obesity, National Institutes of Health,” JAMA, vol. 270, no. 8, pp. 967–974, 1993.

[10] S. Andela, T. L. Burrows, L. A. Baur, D. H. Coyle, C. E. Collins, and M. L. Gow, “Efficacy of very low-energy diet programs for weight loss: a systematic review with meta-analysis of intervention studies in children and adolescents with obesity,” Obesity Reviews, vol. 20, no. 6, pp. 871–882, 2019.

[11] P. Sumithran, L. A. Prendergast, E. Delbridge et al., “Long-term persistence of hormonal adaptations to weight loss,” New England Journal of Medicine, vol. 365, no. 17, pp. 1597–1604, 2011.

[12] A. E. Rothberg, L. N. McEwen, A. T. Kraftson, C. E. Fowler, and W. H. Herman, “Very-low-energy diet for type 2 diabetes: an underutilized therapy?,” Journal of Diabetes and its Complications, vol. 28, no. 4, pp. 506–510, 2014.

[13] L. Rehackova, V. Araujo-Soares, A. J. Adamson, S. Steven, R. Taylor, and F. F. Sniehotta, “Acceptability of a very-low-energy diet in type 2 diabetes: patient experiences and behaviour regulation,” Diabetic Medicine, vol. 34, no. 11, pp. 1554–1567, 2017.

[14] L. Rehackova, V. Araujo-Soares, S. Steven, A. J. Adamson, R. Taylor, and F. F. Sniehotta, “Behaviour change during dietary type 2 diabetes remission: a longitudinal qualitative evaluation of an intervention using a very low energy diet,” Diabetic Medicine, pp. 1–10, 2019.

[15] L. Harris, A. McGarty, L. Hutchison, L. Ellis, and C. Hankey, “Short-term intermittent energy restriction interventions for weight management: a systematic review and meta-analysis,” Obesity Reviews, vol. 19, no. 1, pp. 1–13, 2018.

[16] A. R. Barnosky, K. K. Hody, T. G. Unterman, and K. A. Varady, “Intermittent fasting vs daily calorie restriction for type 2 diabetes prevention: a review of human findings,” Translational Research, vol. 164, no. 4, pp. 302–311, 2014.

[17] N. M. Ashbury, P. Aveyard, A. Nickless et al., “Doctor Referral of Overweight People to Low Energy total diet replacement Treatment (DROPLET): pragmatic randomised controlled trial,” BMJ, vol. 362, article k3760, 2018.

[18] D. E. Kloocker, F. Zaccardi, E. Baldry, M. J. Davies, K. Khunti, and D. R. Webb, “Efficacy of low- and very-low-energy diets in people with type 2 diabetes mellitus: a systematic review and meta-analysis of interventional studies,” Diabetes Obesity and Metabolism, vol. 21, no. 7, pp. 1695–1705, 2019.

[19] L. Rehackova, B. Arnott, V. Araujo-Soares, A. A. Adamson, R. Taylor, and F. F. Sniehotta, “Efficacy and acceptability of very low energy diets in overweight and obese people with type 2 diabetes mellitus: a systematic review with meta-analyses,” Diabetic Medicine, vol. 33, no. 5, pp. 580–591, 2016.

[20] J. P. Higgins and S. Green, Cochrane Handbook for Systematic Reviews of Interventions, John Wiley & Sons, Chichester (UK), 2011.

[21] J. A. C. Sterne, M. A. Hernán, B. C. Reeves et al., “ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions,” BMJ, vol. 355, article i4919, 2016.

[22] G. H. Guyatt, A. D. Oxman, G. E. Vist et al., “GRADE: an emerging consensus on rating quality of evidence and strength of recommendations,” BMJ, vol. 336, no. 7650, pp. 924–926, 2008.

[23] S. Green, Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0, The Cochrane Collaboration, United Kingdom, 2011.

[24] C. Jackness, W. Karmally, G. Febres et al., “Very low-calorie diet mimics the early beneficial effect of Roux-en-Y gastric bypass on insulin sensitivity and β-Cell function in type 2 diabetic patients,” Diabetes, vol. 62, no. 9, pp. 3027–3032, 2013.

[25] J. W. Anderson, V. Brinkman-Kaplan, C. C. Hamilton, J. E. B. Logan, R. W. Collins, and N. J. Gustafson, “Food-containing hypocaloric diets are as effective as liquid-supplement diets for obese individuals with NIDDM,” Diabetes Care, vol. 17, no. 6, pp. 602–604, 1994.

[26] S. Carter, P. M. Clifton, and J. B. Keogh, “The effects of intermittent compared to continuous energy restriction on glycaemic control in type 2 diabetes: a pragmatic pilot trial,” Diabetes Research and Clinical Practice, vol. 122, pp. 106–112, 2016.

[27] S. Carter, P. M. Clifton, and J. B. Keogh, “Effect of intermittent compared with continuous energy restricted diet on glycaemic control in patients with type 2 diabetes: a randomized noninferiority trial,” JAMA Network Open, vol. 1, no. 3, article e180756, 2018.

[28] S. Carter, P. M. Clifton, and J. B. Keogh, “The effect of intermittent compared with continuous energy restriction on glycaemic control in patients with type 2 diabetes: 24-month follow-up of a randomised noninferiority trial,” Diabetes Research and Clinical Practice, vol. 151, pp. 11–19, 2019.

[29] J. Harvey, R. R. Wing, and M. Mullen, “Effects on food cravings of a very low calorie diet or a balanced, low calorie diet,” Appetite, vol. 21, no. 2, pp. 105–115, 1993.

[30] R. R. Wing, M. D. Marcus, R. Salata, L. H. Epstein, S. Miasikewicz, and E. H. Blair, “Effects of a very-low-calorie diet on long-term glycaemic control in obese type 2 diabetic subjects,” Archives of Internal Medicine, vol. 151, no. 7, pp. 1334–1340, 1991.
diet improve outcome?,” *American Journal of Medicine*, vol. 97, no. 4, pp. 354–362, 1994.

[32] M. A. Lips, H. Pijl, J. B. van Klinken et al., "Roux-en-Y gastric bypass and calorie restriction induce comparable time-dependent effects on thyroid hormone function tests in obese female subjects,” *European Journal of Endocrinology*, vol. 169, no. 3, pp. 339–347, 2013.

[33] L. Plum, L. Ahmed, G. Febres et al., "Comparison of glucostatic parameters after hypocaloric diet or bariatric surgery and equivalent weight loss,” *Obesity*, vol. 19, no. 11, pp. 2149–2157, 2011.

[34] A. Cinkajzlová, M. Mráz, Z. Lacinová et al., "Angiopoietin-like protein 3 and 4 in obesity, type 2 diabetes mellitus, and malnutrition: the effect of weight reduction and realimentation,” *Nutrition & Diabetes*, vol. 8, no. 1, p. 21, 2018.

[35] S. Steven, K. G. Hollingsworth, P. K. Small et al., "Calorie restriction and not glucagon-like peptide-1 explains the acute improvement in glucose control after gastric bypass in type 2 diabetes,” *Diabetic Medicine*, vol. 33, no. 12, pp. 1723–1731, 2016.

[36] R. B. Paisey, P. Harvey, S. Rice et al., "An intensive weight loss programme in established type 2 diabetes and controls: effects on weight and atherosclerosis risk factors at 1 year,” *Diabetic Medicine*, vol. 15, no. 1, pp. 73–79, 1998.

[37] R. B. Paisey, J. Frost, P. Harvey et al., "Five year results of a prospective very low calorie diet or conventional weight loss programme in type 2 diabetes,” *Journal of Human Nutrition and Dietetics*, vol. 15, no. 1, pp. 121–127, 2002.

[38] R. Paisey, P. Harvey, S. Rice et al., "Short-term results of an open trial of very low calorie diet or intensive conventional diet in Type 2 diabetes,” *Practical Diabetes International*, vol. 12, no. 6, pp. 263–267, 1995.

[39] C. Li, B. Sadraie, N. Steckhan et al., "Effects of a one-week fasting therapy in patients with type-2 diabetes mellitus and metabolic syndrome - a randomized controlled explorative study,” *Experimental and Clinical Endocrinology & Diabetes*, vol. 125, no. 9, pp. 618–624, 2017.

[40] K. V. Williams, M. L. Mullen, D. E. Kelley, and R. R. Wing, "The effect of short periods of caloric restriction on weight loss and glycemic control in type 2 diabetes,” *Diabetes Care*, vol. 21, no. 1, pp. 2–8, 1998.

[41] M. Laakso, M. Uusitupa, J. Takala, H. Majander, T. Reijonen, and I. Penttilä, "Effects of hypocaloric diet and insulin therapy on metabolic control and mechanisms of hyperglycaemia in obese non-insulin-dependent diabetic subjects,” *Metabolism*, vol. 37, no. 11, pp. 1092–1100, 1988.

[42] M. E. J. Lean, "Low-calorie diets in the management of type 2 diabetes mellitus,” *Nature Reviews Endocrinology*, vol. 15, no. 5, article 186, pp. 251-252, 2019.

[43] M. J. Franz, J. J. VanWormer, A. L. Crain et al., "Weight-Loss Outcomes: A Systematic Review and Meta-Analysis of Weight-Loss Clinical Trials with a Minimum 1-Year Follow-Up,” *Journal of the American Dietetic Association*, vol. 107, no. 10, pp. 1755–1767, 2007.

[44] A. C. Feldstein, G. A. Nichols, D. H. Smith et al., "Weight change in diabetes and glycemic and blood pressure control,” *Diabetes Care*, vol. 31, no. 10, pp. 1960–1965, 2008.

[45] L. Aucott, A. Poobalan, W. C. S. Smith et al., "Weight loss in obese diabetic and non-diabetic individuals and long-term diabetes outcomes-a systematic review,” *Diabetes Obesity and Metabolism*, vol. 6, no. 2, pp. 85–94, 2004.